Covid-19 roundup: Old test sam­ples sug­gest Omi­cron has been in Eu­rope for weeks; US to tight­en trav­el re­stric­tions  ...

4 years ago
Coronavirus

'Don't freak out': Ugur Sahin takes a dif­fer­ent tone on Omi­cron than his mR­NA coun­ter­part — re­ports

4 years ago
Coronavirus

Look­ing to run with Big Phar­ma, a ra­dio­phar­ma start­up with back­ing from At­las, RA thinks it has the chops to com­pete

4 years ago
Financing
Startups

Sanofi snaps up new vac­cine can­di­date and de­vis­es mR­NA game plan around it — but not for what you think

4 years ago
Deals
Cell/Gene Tx

Apol­lo Health Ven­tures pumps an­oth­er $180M in­to the bur­geon­ing race to slow ag­ing

4 years ago
Financing

FDA ad­comm nar­row­ly votes in fa­vor of Mer­ck­'s an­tivi­ral for out­pa­tient Covid-19

4 years ago
FDA+
Coronavirus

Ap­peals court puts the fi­nal nail in the cof­fin for Tec­fidera patent, adding to Bio­gen's bur­geon­ing set­backs

4 years ago
Pharma

Drug de­vel­op­ment 101: Gilead goes back to school with new pro­gram to at­tract Black and His­pan­ic stu­dents to phar­ma

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Ab­b­Vie’s Hu­mi­ra TV turns fo­cus to HS skin con­di­tion; Sanofi amps par­ent­ing pol­i­cy

4 years ago
Pharma
Marketing

Sci­wind gets li­cens­ing deal with Sanofi for meta­bol­ic dis­ease can­di­dates; Im­mu­ni­ty­Bio and En­Gene­IC reach deal for ...

4 years ago
News Briefing

As lead drug runs in­to a wall, De­ci­phera slims down its pipeline, puts 140 jobs on the chop­ping block

4 years ago
People
R&D

FDA can­cels ODAC meet­ing this week as Se­cu­ra Bio pulls ac­cel­er­at­ed ap­proval

4 years ago
FDA+

Im­muno­Gen touts a PhI­II come­back in ovar­i­an can­cer, eye­ing a 2022 ac­cel­er­at­ed ap­proval

4 years ago
R&D
FDA+

FDA rais­es con­cerns over TG Ther­a­peu­tic­s' sur­vival da­ta, plans to con­vene ODAC

4 years ago
FDA+

Start­ing from scratch: Vi­a­tris’ new brand, cul­ture set­tle in 1 year af­ter My­lan, Up­john merg­er

4 years ago
Pharma
Marketing

As­traZeneca turns down the TV vol­ume to dri­ve up at­ten­tion with Fasen­ra asth­ma cam­paign

4 years ago
Pharma
Marketing

Glax­o­SmithK­line poach­es Pfiz­er's vi­ral vac­cines lead in rush to cap­i­tal­ize on fu­ture of mR­NA

4 years ago
People

How to use reg­istry da­ta to sup­port FDA de­ci­sion mak­ing: Agency ex­plains in new guid­ance

4 years ago
R&D
FDA+

Af­ter re­fut­ing a sup­posed da­ta leak as 'fal­si­fied', Ole­ma re­veals first clin­i­cal da­ta for lead pro­gram — shares ...

4 years ago
R&D

In­tro­duc­ing End­points Stu­dio, a new way to ad­ver­tise with End­points-craft­ed brand­ing cam­paigns

4 years ago
Publisher's note

Af­ter Big Phar­ma sparked in­ter­est in the US, Ablaze looks to bring ra­dio­phar­ma­ceu­ti­cals over­seas

4 years ago
Financing
Startups

Covid-19 roundup: As­pen to pro­duce gener­ic J&J vac­cine for Africa; First boost­ers for un­der-18-year-olds could come ...

4 years ago
Coronavirus

'This is not go­ing to be good': Mod­er­na CEO Ban­cel warns of a 'ma­te­r­i­al drop' in vac­cine ef­fi­ca­cy as Omi­cron spreads

4 years ago
R&D

Chi­na’s top mR­NA con­tender is ready to go. And Soft­Bank just led a cash in­fu­sion push­ing it over the $1B line

4 years ago
Financing
China
First page Previous page 608609610611612613614 Next page Last page
A service from the Financial Times